CO5031285A1 - Triarilimidazoles - Google Patents

Triarilimidazoles

Info

Publication number
CO5031285A1
CO5031285A1 CO00026001A CO00026001A CO5031285A1 CO 5031285 A1 CO5031285 A1 CO 5031285A1 CO 00026001 A CO00026001 A CO 00026001A CO 00026001 A CO00026001 A CO 00026001A CO 5031285 A1 CO5031285 A1 CO 5031285A1
Authority
CO
Colombia
Prior art keywords
triarilimidazoles
andone
6alkyl
chr
pharmaceuticals
Prior art date
Application number
CO00026001A
Other languages
English (en)
Inventor
Lorraine Burgess Joelle
James Francis Callahan
Original Assignee
Smithkline Beechman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beechman Corp filed Critical Smithkline Beechman Corp
Publication of CO5031285A1 publication Critical patent/CO5031285A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Un compuesto de la fórmula (I) o una sal farmacéuticamenteaceptable del mismo:en la que R1 es naftilo, antracenilo, o fenilo opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo constituido por halo, alcoxi C1-6 , alquil C1-6 -tio, alquilo C1-6 , -O-(CH2 )n -Ph, -S-(CH2 )n -Ph, ciano, fenilo y CO2 R, en donde R es hidrógeno o alquilo C1-6 y n es 0, 1, 2 ó 3; o R1 es fenilo condensado con un anillo cíclico aromático o no aromático de 5-7 miembros, en donde dicho anillo cíclico contiene opcionalmente hasta dos heteroátomos, seleccionados independientemente entre N, O y S;R2 es H, NH(CH2 )n -Ph o NH-alquilo C1-6 , en donde n es 0, 1, 2 ó 3;R3 es CO2 H, CONH2 , CN, NO2 , alquil C1-6 -tio, SO2 -alquilo C1-6 , alcoxi C1-6 , SONH2 , CONHOH, NH2 , CHO, CH2 OH, CH2 NH2 ó CO2 R, en donde R es hidrógeno o alquilo C1-6 ; y uno de X1 y X2 es N o CR´; y el otro es NR´ o CHR´ en donde R´ es hidrógeno, OH, alquilo C1-6 o cicloalquilo C3-7 ; o cuando uno de X1 y X2 es N o CR´ , entonces el otro puede ser S u O.Un método para inhibir la ruta que produce señales por medio de TGF-ß en mamíferos, que comprende administrar a un mamífero que necesita de dicho tratamiento, una cantidad terapéuticamente eficaz de un compuesto según una cualquiera de las reivindicaciones 1 a 8, o una de sus sales farmacéuticamente aceptables.
CO00026001A 1999-04-09 2000-04-10 Triarilimidazoles CO5031285A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12868799P 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
CO5031285A1 true CO5031285A1 (es) 2001-04-27

Family

ID=22436501

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00026001A CO5031285A1 (es) 1999-04-09 2000-04-10 Triarilimidazoles

Country Status (9)

Country Link
US (1) US6465493B1 (es)
EP (1) EP1169317B1 (es)
JP (1) JP2002541253A (es)
AT (1) ATE231143T1 (es)
AU (1) AU4798000A (es)
CO (1) CO5031285A1 (es)
DE (1) DE60001229T2 (es)
ES (1) ES2187473T3 (es)
WO (1) WO2000061576A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
AU2000250285B2 (en) * 2000-05-19 2006-05-04 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Inhibition of SMAD3 to prevent fibrosis and improve wound healing
JP2004517068A (ja) * 2000-11-16 2004-06-10 スミスクライン・ビーチャム・コーポレイション 化合物
GB0100762D0 (en) * 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
UA76461C2 (en) 2001-05-24 2006-08-15 Lilly Co Eli Pyrrazole derivatives as pharmaceutical agents, use thereof, a pharmaceutical composition on their basis
GB0127430D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1554272B1 (en) 2002-08-09 2006-10-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
CN1681501A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的吡唑衍生物
BR0314286A (pt) 2002-09-18 2005-08-02 Pfizer Prod Inc Compostos de isotiazol e isoxazol como inibidores do fator de crescimento transformante (tgf)
EA200500378A1 (ru) * 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
PL375974A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
MXPA05002332A (es) * 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
US20040192583A1 (en) * 2002-12-19 2004-09-30 Satyanarayana Medicherla Treatment of obesity and associated conditions with TGF-beta inhibitors
AU2003300099A1 (en) * 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
JPWO2004108160A1 (ja) * 2003-06-05 2006-07-27 日本新薬株式会社 骨形成促進増強剤及びそのスクリーニング方法
CA2539162A1 (en) * 2003-09-17 2005-03-31 Sumitomo Chemical Company, Limited Cinnamoyl derivatives and use thereof
JP4815773B2 (ja) * 2003-09-17 2011-11-16 住友化学株式会社 シンナモイル化合物及びその用途
JP2006104061A (ja) * 2003-09-17 2006-04-20 Sumitomo Chemical Co Ltd シンナモイル化合物含有ｉ型コラーゲン遺伝子転写抑制組成物。
RU2367661C2 (ru) 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
US20080319012A1 (en) 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP2008506787A (ja) * 2004-07-29 2008-03-06 シェーリング−プラウ・リミテッド 動物においてミオスタチン活性を調節または阻害して赤身組織の成長増加を導くａｌｋ５インヒビターの使用
WO2007011626A2 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
WO2008066626A2 (en) 2006-10-25 2008-06-05 The Rockefeller University METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
EP2108017A2 (en) * 2007-01-30 2009-10-14 Biogen Idec MA, Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2008136739A1 (en) * 2007-05-04 2008-11-13 Jana Pickova Compound feed for aquaculture
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
RS55735B1 (sr) 2007-08-03 2017-07-31 Summit (Oxford) Ltd Kombinacije lekova za lečenje dišenove mišićne distrofije
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US9446175B2 (en) * 2011-06-03 2016-09-20 Yale University Compositions and methods for treating and preventing neointimal stenosis
TR201808033T4 (tr) 2011-07-13 2018-06-21 Tiumbio Co Ltd Alk5 ve veya alk4 inhibitörleri olarak 2 pridil ikameli imidazollar.
DK2855665T3 (da) 2012-05-30 2019-11-04 Univ Cornell Tilvejebringelse af funktionelle og bestandige endotele celler fra humane amnionvæske-afledte celler
ES2791778T3 (es) 2012-08-01 2020-11-05 Ikaika Therapeutics Llc Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4
CN105229144A (zh) 2013-02-22 2016-01-06 细胞动力学国际有限公司 通过组合的遗传工程和化学工程经由正向编程产生肝细胞
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10961531B2 (en) 2013-06-05 2021-03-30 Agex Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
WO2015106158A1 (en) 2014-01-09 2015-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
KR102346489B1 (ko) 2014-04-18 2021-12-31 교토후고리츠다이가쿠호진 골아 세포의 조제 방법 및 골아 세포 유도제
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US11541149B2 (en) 2015-12-11 2023-01-03 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
CN113347990A (zh) 2018-12-21 2021-09-03 西北大学 膜联蛋白在预防和治疗肌膜损伤中的用途
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
JP2023533850A (ja) 2020-07-15 2023-08-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ａｌｋ５阻害剤としてのピリドオキサジンアミノ誘導体
BR112023000588A8 (pt) 2020-07-15 2023-05-09 Chiesi Farm Spa Derivados de piridazinil amino como inibidores de alk5
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB138101A (es)
CH561716A5 (es) * 1971-05-10 1975-05-15 Ciba Geigy Ag
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
DE69433501T2 (de) * 1993-11-08 2004-11-04 Smithkline Beecham Corp. Oxazole zur behandlung von zytokinvermittelten erkrankungen
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
JPH11180958A (ja) * 1997-12-24 1999-07-06 Yamanouchi Pharmaceut Co Ltd 新規アミン誘導体

Also Published As

Publication number Publication date
US6465493B1 (en) 2002-10-15
ES2187473T3 (es) 2003-06-16
ATE231143T1 (de) 2003-02-15
DE60001229T2 (de) 2003-10-30
WO2000061576A1 (en) 2000-10-19
DE60001229D1 (de) 2003-02-20
EP1169317B1 (en) 2003-01-15
EP1169317A1 (en) 2002-01-09
JP2002541253A (ja) 2002-12-03
AU4798000A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
CO5031285A1 (es) Triarilimidazoles
CO5280078A1 (es) Compuestos
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MXPA03002911A (es) Compuestos quimicos.
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
MXPA02012076A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
WO2002062767A1 (fr) Nouveaux derives de quinazoline
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU3626895A (en) Quinazolinone pharmaceuticals and use thereof
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
ATE213241T1 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
ATE286887T1 (de) Antibakterielle mittel
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
SE9901901D0 (sv) Compounds
IL159493A0 (en) Pharmaceutical formulation containing an ltb4 antagonist
SE9603284D0 (sv) New compounds